{"id":9194,"date":"2025-01-12T14:18:57","date_gmt":"2025-01-12T10:48:57","guid":{"rendered":"https:\/\/cedalco.com\/project\/ribocedal\/"},"modified":"2026-01-09T19:47:35","modified_gmt":"2026-01-09T16:17:35","slug":"ribocedal","status":"publish","type":"dt_portfolio","link":"https:\/\/cedalco.com\/en\/project\/ribocedal\/","title":{"rendered":"Ribocedal"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"9194\" class=\"elementor elementor-9194 elementor-9176\" data-elementor-post-type=\"dt_portfolio\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-87b4b9b elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"87b4b9b\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-ff50316\" data-id=\"ff50316\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-4ae8e66 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"4ae8e66\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-e489d4a\" data-id=\"e489d4a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3620e73 elementor-widget elementor-widget-image\" data-id=\"3620e73\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/cedalco.com\/wp-content\/uploads\/2025\/01\/ribocedal.jpeg\" data-elementor-open-lightbox=\"yes\" data-elementor-lightbox-title=\"ribocedal\" data-e-action-hash=\"#elementor-action%3Aaction%3Dlightbox%26settings%3DeyJpZCI6OTE4MCwidXJsIjoiaHR0cHM6XC9cL2NlZGFsY28uY29tXC93cC1jb250ZW50XC91cGxvYWRzXC8yMDI1XC8wMVwvcmlib2NlZGFsLmpwZWcifQ%3D%3D\">\n\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"389\" height=\"406\" src=\"https:\/\/cedalco.com\/wp-content\/uploads\/2025\/01\/ribocedal.jpeg\" class=\"elementor-animation-float attachment-full size-full wp-image-9180\" alt=\"\" srcset=\"https:\/\/cedalco.com\/wp-content\/uploads\/2025\/01\/ribocedal.jpeg 389w, https:\/\/cedalco.com\/wp-content\/uploads\/2025\/01\/ribocedal-287x300.jpeg 287w\" sizes=\"(max-width: 389px) 100vw, 389px\" title=\"\">\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">Click on the photo to enlarge <i class=\"fa fa-search-plus\" aria-hidden=\"true\"><\/i><\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-71106f4\" data-id=\"71106f4\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8f49ed9 elementor-widget__width-auto elementor-widget-mobile__width-inherit elementor-widget elementor-widget-theme-post-title elementor-page-title elementor-widget-heading\" data-id=\"8f49ed9\" data-element_type=\"widget\" data-widget_type=\"theme-post-title.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Ribocedal<sup>\u00ae<\/sup><\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-295c85a elementor-widget elementor-widget-spacer\" data-id=\"295c85a\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-af6eda1 content-align-mobile-left elementor-widget__width-initial elementor-widget-mobile__width-inherit icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"af6eda1\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-af6eda1\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tGeneric Name\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Bendamustine Hydrochloride <\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0820bd1 content-align-mobile-left elementor-widget__width-initial elementor-widget-mobile__width-inherit icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"0820bd1\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-0820bd1\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tBrand Name\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\"><sup>\u00ae<\/sup>RiboCedal<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0417094 elementor-widget__width-initial elementor-widget-mobile__width-inherit content-align-mobile-left icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"0417094\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-0417094\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tDrug Class\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Alkylating agent with purine-analog\u2013like properties<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8ebd9f0 elementor-widget__width-initial elementor-widget-mobile__width-inherit content-align-mobile-left icon-box-vertical-align-top icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"8ebd9f0\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-8ebd9f0\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<a class=\"elementor-icon-div\" >\t\t\t\t\t\t<div class=\"elementor-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle-notch\"><\/i>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/a>\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a >\t\t\t\t\t\t\t\tDosage Form\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"box-description\">Powder for Concentrate for Solution for Infusion \n25 mg & 100 mg\n<\/div>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-1846fd2 the7-e-tabs-view-vertical icon-align-left elementor-widget elementor-widget-the7-tabs\" data-id=\"1846fd2\" data-element_type=\"widget\" data-settings=\"{&quot;accordion_breakpoint&quot;:&quot;mobile&quot;}\" data-widget_type=\"the7-tabs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t<div class=\"the7-e-tabs-wrapper\">\n\t\t<div class=\"the7-e-tabs-nav-wrapper\">\n\t\t\t<div class=\"the7-e-tabs-nav-scroll-wrapper\">\n\t\t\t\t<div class=\"the7-e-tabs-nav\" role=\"tablist\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-2541\" class=\"the7-e-tab-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"the7-e-tab-content-2541\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tIndications\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-2542\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-2542\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus-slash\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tContradications\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-2543\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-2543\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-list-ul\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tWarnings and Precautions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-2544\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-2544\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-hand-holding-medical\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDosage & Administration\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-2545\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-2545\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"far fa-bell\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tAdverse Reactions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-2546\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-2546\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fab fa-confluence\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDrug Interactions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-2547\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-2547\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-baby\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\t Pregnancy and Lactation\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t<div id=\"the7-e-tab-title-2548\" class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"8\" role=\"tab\" tabindex=\"-1\" aria-controls=\"the7-e-tab-content-2548\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-box\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tStorage Conditions\t\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div class=\"the7-e-tab-nav-button left-button\"><\/div>\n\t\t\t<div class=\"the7-e-tab-nav-button right-button\"><\/div>\n\t\t<\/div>\n\t\t<div class=\"the7-e-tabs-content\" role=\"tablist\" aria-orientation=\"vertical\">\n\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"1\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-2541\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tIndications\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-2541\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"1\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-2541\" tabindex=\"0\" hidden=\"false\"><ul><li>First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.<\/li><li>Indolent non-Hodgkin&#8217;s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.<\/li><\/ul><p>Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"2\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2542\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-virus-slash\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tContradications\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-2542\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"2\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-2542\" tabindex=\"0\" hidden=\"hidden\"><ul><li>Hypersensitivity to the active substance or to any of the excipients such as Mannitol.<\/li><li>During breastfeeding<\/li><li>Severe hepatic impairment (serum bilirubin &gt; 3.0 mg\/dl)<\/li><li>Jaundice<\/li><li>Severe bone marrow suppression and severe blood count alterations (leukocyte and\/or platelet values dropped to &lt; 3,000\/\u00b5l or &lt; 75,000\/\u00b5l, respectively)<\/li><li>Major surgery less than 30 days before start of treatment<\/li><li>Infections, especially involving leukocytopenia<\/li><li>Yellow fever vaccination<\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"3\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2543\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-list-ul\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tWarnings and Precautions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-2543\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"3\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-2543\" tabindex=\"0\" hidden=\"hidden\"><p><em><u>Myelosuppression<\/u><\/em><\/p><p>Patients treated with Ribocedal<sup>\u00ae <\/sup>may experience myelosuppression. In the event of treatment-related myelosuppression, leukocytes, platelets, haemoglobin, and neutrophils must be monitored at least weekly. Prior to the initiation of the next cycle of therapy, the following parameters are recommended: Leukocyte and\/or platelet values &gt; 4,000\/\u00b5l or &gt; 100,000\/\u00b5l, respectively.<\/p><p><em><u>Infections<\/u><\/em><\/p><p>Serious and fatal infections have occurred with Ribocedal<sup>\u00ae<\/sup>, including bacterial (sepsis, pneumonia) and opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP), varicella zoster virus (VZV) and cytomegalovirus (CMV). Cases of progressive multifocal leukoencephalopathy (PML) including fatal ones have been reported following the use of bendamustine mainly in combination with rituximab or obinutuzumab. Treatment with Ribocedal<sup>\u00ae<\/sup> may cause prolonged lymphocytopenia (&lt; 600\/\u03bcl) and low CD4-positive T-cell (T-helper cell) counts (&lt; 200\/\u03bcl) for at least 7\u20139 months after the completion of treatment. Lymphocytopenia and CD4-positive T-cell depletion are more pronounced when Ribocedal<sup>\u00ae<\/sup> is combined with rituximab. Patients with lymphopenia and low CD4-positive T-cell count following treatment with Ribocedal<sup>\u00ae<\/sup> are more susceptible to (opportunistic) infections. In case of low CD4-positive T-cell counts (&lt; 200 \u00b5\/l) Pneumocystis jirovecii pneumonia (PJP) prophylaxis should be considered. All patients should be monitored for respiratory signs and symptoms throughout treatment. Patients should be advised to report new signs of infection, including fever or respiratory symptoms promptly. Discontinuation of Ribocedal<sup>\u00ae<\/sup> should be considered if there are signs of (opportunistic) infections.<\/p><p>Consider PML in the differential diagnosis in patients with new or worsening neurological, cognitive or behavioural signs or symptoms. If PML is suspected then appropriate diagnostic evaluations should be undertaken and treatment suspended until PML is excluded.<\/p><p><em><u>Hepatitis B reactivation<\/u><\/em><\/p><p>Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received bendamustine hydrochloride. Some cases resulted in acute hepatic failure or a fatal outcome. Patients should be tested for HBV infection before initiating treatment with Ribocedal<sup>\u00ae<\/sup>. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B tests (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with Ribocedal<sup>\u00ae <\/sup>should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.<\/p><p><em><u>Skin reactions<\/u><\/em><\/p><p>A number of skin reactions have been reported. These events have included rash, severe cutaneous reactions and bullous exanthema. Cases of Stevens \u2013 Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), some fatal, have been reported with the use of bendamustine hydrochloride. Patients should be advised of the signs and symptoms of these reactions by their prescribers and should be told to seek medical attention immediately if they develop these symptoms. Some events occurred when bendamustine hydrochloride was given in combination with other anticancer agents, so the precise relationship is uncertain. Where skin reactions occur, they may be progressive and increase in severity with further treatment. When skin reactions are progressive, Ribocedal<sup>\u00ae <\/sup>should be withheld or discontinued. For severe skin reactions with suspected relationship to Ribocedal<sup>\u00ae <\/sup>, treatment should be discontinued.<\/p><p><em><u>Non-melanoma skin cancer<\/u><\/em><\/p><p>In clinical studies, an increased risk for non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) has been observed in patients treated with bendamustine containing therapies. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.<\/p><p><em><u>Cardiac disorders<\/u><\/em><\/p><p>During treatment with Ribocedal<sup>\u00ae <\/sup>the concentration of potassium in the blood of patients with cardiac disorders must be closely monitored and potassium supplement must be given when K<sup>+<\/sup>\u00a0&lt;3.5 mEq\/l, and ECG measurement must be performed.<\/p><p>Fatal cases of myocardial infarction and cardiac failure have been reported with bendamustine hydrochloride treatment. Patients with concurrent or history of cardiac disease should be observed closely.<\/p><p><em><u>Nausea, vomiting<\/u><\/em><\/p><p>An antiemetic may be given for the symptomatic treatment of nausea and vomiting.<\/p><p><em><u>Tumour lysis syndrome<\/u><\/em><\/p><p>Tumour lysis syndrome (TLS) associated with bendamustine hydrochloride treatment has been reported in patients in clinical trials. The onset tends to be within 48 hours of the first dose of Ribocedal<sup>\u00ae<\/sup> and, without intervention, may lead to acute renal failure and death. Preventive measures such as adequate hydration and close monitoring of blood chemistry, particularly potassium and uric acid levels, and the use of hypouricemic agents (allopurinol and rasburicase) should be considered prior to therapy. There have been a few cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis reported when Ribocedal<sup>\u00ae<\/sup> and allopurinol were administered concomitantly.<\/p><p><em><u>Anaphylaxis<\/u><\/em><\/p><p>Infusion reactions to bendamustine hydrochloride have occurred commonly in clinical trials. Symptoms are generally mild and include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred. Patients must be asked about symptoms suggestive of infusion reactions after their first cycle of therapy. Measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids must be considered in subsequent cycles in patients who have previously experienced infusion reactions.<\/p><p>Patients who experienced Grade 3 or worse allergic-type reactions were typically not re-challenged.<\/p><p><em><u>Contraception<\/u><\/em><\/p><p>Ribocedal<sup>\u00ae <\/sup>is teratogenic and mutagenic.<\/p><p>Women should not become pregnant during treatment. Male patients should not father a child during and up to 6 months after treatment. They should seek advice about sperm conservation prior to treatment with Ribocedal<sup>\u00ae <\/sup>because of possible irreversible infertility.<\/p><p><em><u>Extravasation<\/u><\/em><\/p><p>An extravasal injection should be stopped immediately. The needle should be removed after a short aspiration. Thereafter the affected area of tissue should be cooled. The arm should be elevated. Additional treatments like the use of corticosteroids are not of clear benefit.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"4\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2544\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-hand-holding-medical\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDosage & Administration\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-2544\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"4\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-2544\" tabindex=\"0\" hidden=\"hidden\"><p>Ribocedal<sup>\u00ae<\/sup> must only be administered under the supervision of a physician qualified in the use of anti\u00adcancer chemotherapy.<\/p><p><strong>Dosage:<\/strong><\/p><p><em>Monotherapy for chronic lymphocytic leukaemia<\/em><\/p><p>100 mg\/m<sup>2<\/sup>\u00a0body surface area Ribocedal<sup>\u00ae<\/sup>on days 1 and 2; every 4 weeks.<\/p><p><em>Monotherapy for indolent non-Hodgkin&#8217;s lymphomas refractory to rituximab<\/em><\/p><p>120 mg\/m<sup>2<\/sup>\u00a0body surface area Ribocedal<sup>\u00ae<\/sup>on days 1 and 2; every 3 weeks.<\/p><p><em>Multiple myeloma<\/em><\/p><p>120 &#8211; 150 mg\/m<sup>2<\/sup>\u00a0body surface area Ribocedal<sup>\u00ae <\/sup>on days 1 and 2, 60 mg\/m<sup>2<\/sup>\u00a0body surface area prednisone i.v. or per os on days 1 to 4; every 4 weeks.<\/p><p>Poor bone marrow function is related to increased chemotherapy-induced haematological toxicity. Treatment should not be started if leukocyte and\/or platelet values have dropped to &lt; 3,000\/\u00b5l or &lt; 75,000\/\u00b5l, respectively.<\/p><p>Treatment should be terminated or delayed if leukocyte and\/or platelet values have dropped to &lt; 3,000\/\u00b5l or &lt; 75,000\/\u00b5l, respectively. Treatment can be continued after leukocyte values have increased to &gt; 4,000\/\u00b5l and platelet values to &gt; 100,000\/\u00b5l.<\/p><p>The leukocyte and platelet Nadir is reached after 14-20 days with regeneration after 3-5 weeks. During therapy free intervals strict monitoring of the blood count is recommended.<\/p><p>In case of non-haematological toxicity dose reductions have to be based on the worst CTC grades in the preceding cycle. A 50% dose reduction is recommended in case of CTC grade 3 toxicity. An interruption of treatment is recommended in case of CTC grade 4 toxicity.<\/p><p>If a patient requires a dose modification the individually calculated reduced dose must be given on day 1 and 2 of the respective treatment cycle.<\/p><p><em>Hepatic impairment<\/em><\/p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with mild hepatic impairment (serum bilirubin &lt; 1.2 mg\/dl). A 30% dose reduction is recommended in patients with moderate hepatic impairment (serum bilirubin 1.2 &#8211; 3.0 mg\/dl).<\/p><p>No data is available in patients with severe hepatic impairment (serum bilirubin values of &gt; 3.0 mg\/dl).<\/p><p><em>Renal impairment<\/em><\/p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with a creatinine clearance of &gt; 10 ml\/min. Experience in patients with severe renal impairment is limited.<\/p><p><em>Paediatric population<\/em><\/p><p>The safety and efficacy of Ribocedal<sup>\u00ae<\/sup> in children have not yet been established. Current available data is not sufficient to make a recommendation on posology.<\/p><p><em>Elderly patients<\/em><\/p><p>There is no evidence that dose adjustments are necessary in elderly patients.<\/p><p><strong>Method of administration<\/strong><\/p><p>For intravenous infusion over 30 &#8211; 60 minutes.<\/p><p>Infusion must be administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.<\/p><p><em>Precautions to be taken before handling or administering the medicinal product.<\/em><\/p><p>Aseptically reconstitute each Bendamustine hydrochloride for Injection vial as follows:<\/p><p>\u2713 25 mg Bendamustine hydrochloride for Injection vial: Add 5 mL of only Sterile Water for Injection, USP.<\/p><p>\u2713100 mg Bendamustine hydrochloride for Injection vial: Add 20 mL of only Sterile Water for Injection, USP<\/p><p>Shake well to yield a clear, colorless to a pale-yellow solution with a bendamustine HCl concentration of 5 mg\/mL. The lyophilized powder should completely dissolve in 5 minutes. The reconstituted solution must be transferred to the infusion bag within 30 minutes of reconstitution. If particulate matter is observed, the reconstituted product should not be used.<\/p><p>Aseptically withdraw the volume needed for the required dose (based on 5 mg\/mL concentration) and immediately transfer to a 500 mL infusion bag of 0.9% Sodium Chloride Injection, USP (normal saline). As an alternative to 0.9% Sodium Chloride Injection, USP (normal saline), a 500 mL infusion bag of 2.5% Dextrose\/0.45% Sodium Chloride Injection, USP, may be considered. The resulting final concentration of bendamustine HCl in the infusion bag should be within 0.2 to 0.6 mg\/mL. After transferring, thoroughly mix the contents of the infusion bag. Use Sterile Water for Injection, USP, for reconstitution and then either 0.9% Sodium Chloride Injection,<\/p><p>USP, or 2.5% Dextrose\/0.45% Sodium Chloride Injection, USP, for dilution, as outlined above. No other diluents have been shown to be compatible.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"5\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2545\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"far fa-bell\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tAdverse Reactions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-2545\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"5\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-2545\" tabindex=\"0\" hidden=\"hidden\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Side effects with ALMETRA\u00ae may include:<\/p><ul><li><strong>&gt;10%:<\/strong><\/li><\/ul><p>Cardiovascular: Peripheral edema (13%)<\/p><p>Central nervous system: Fatigue (9% to 57%), headache (21%), dizziness (14%), chills (6% to 14%), insomnia (13%)<\/p><p>Dermatologic: Skin rash (8% to 16%)<\/p><p>Endocrine &amp; metabolic: Weight loss (7% to 18%), dehydration (14%)<\/p><p>Gastrointestinal: Nausea (20% to 75%), vomiting (16% to 40%), diarrhea (9% to 37%), constipation (29%), anorexia (23%), stomatitis (15%), abdominal pain (13%), decreased appetite (13%), dyspepsia (11%)<\/p><p>Hematologic &amp; oncologic: Lymphocytopenia (68% to 99%; grades 3\/4: 47% to 94%), bone marrow depression (grades 3\/4: 98%; nadir: in week 3), leukopenia (61% to 94%; grades 3\/4: 28% to 56%), decreased hemoglobin (88% to 89%; grades 3\/4: 11% to 13%), decreased neutrophils (75% to 86%; grades 3\/4: 43% to 60%), thrombocytopenia (77% to 86%; grades 3\/4: 11% to 25%)<\/p><p>Hepatic: Increased serum bilirubin (34%)<\/p><p>Neuromuscular &amp; skeletal: Back pain (14%), weakness (8% to 11%)<\/p><p>Respiratory: Cough (4% to 22%), dyspnea (16%)<\/p><p>Miscellaneous: Fever (24% to 34%)<\/p><ul><li><strong>1-10%:<\/strong><\/li><\/ul><p>Cardiovascular: Tachycardia (7%), chest pain (6%), hypotension (6%), exacerbation of hypertension (3%)<\/p><p>Central nervous system: Anxiety (8%), depression (6%), pain (6%)<\/p><p>Dermatologic: Pruritus (5% to 6%), hyperhidrosis (5%), night sweats (5%), xeroderma (5%)<\/p><p>Endocrine &amp; metabolic: Hypokalemia (9%), hyperuricemia (7%), hyperglycemia (grades 3\/4: 3%), hypocalcemia (grades 3\/4: 2%), hyponatremia (grades 3\/4: 2%)<\/p><p>Gastrointestinal: Gastroesophageal reflux disease (10%), xerostomia (9%), dysgeusia (7%), oral candidiasis (6%), abdominal distention (5%), upper abdominal pain (5%)<\/p><p>Genitourinary: Urinary tract infection (10%)<\/p><p>Hematologic &amp; oncologic: Febrile neutropenia (grades 3\/4: 6%)<\/p><p>Hepatic: Increased serum ALT (grades 3\/4: 3%), increased serum AST (grades 3\/4: 1%)<\/p><p>Hypersensitivity: Hypersensitivity (5%)<\/p><p>Infection: Herpes zoster (10%), infection (6%), herpes simplex infection (3%)<\/p><p>Local: Infusion site pain (6%), catheter pain (5%)<\/p><p>Neuromuscular &amp; skeletal: Arthralgia (6%), limb pain (5%), ostealgia (5%)<\/p><p>Renal: Increased serum creatinine (grades 3\/4: 2%)<\/p><p>Respiratory: Upper respiratory tract infection (10%), sinusitis (9%), pharyngolaryngeal pain (8%), pneumonia (8%), nasopharyngitis (6% to 7%), nasal congestion (5%), wheezing (5%)<\/p><ul><li><strong>Frequency not defined:<\/strong><\/li><\/ul><p>Central nervous system: Drowsiness, malaise<\/p><p>Dermatologic: Dermatitis, skin necrosis<\/p><p>Gastrointestinal: Mucositis<\/p><p>Hematologic &amp; oncologic: Hemolysis<\/p><ul><li><strong>&lt;1%:<\/strong><\/li><\/ul><p>\u00a0postmarketing, and\/or case reports: Acute renal failure, anaphylactoid reaction, anaphylaxis, atrial fibrillation, bronchogenic carcinoma, bullous rash, cardiac failure, dermatological reaction (toxic), DRESS syndrome, erythema, extravasation injury, hepatitis, hepatotoxicity, injection site reaction (including irritation, pain, phlebitis, pruritus, swelling), myelodysplastic syndrome, myeloid leukemia (acute), myocardial infarction, neutropenic sepsis, palpitations, pancytopenia, pneumonia ( Pneumocystis jirovecii), pneumonitis, pulmonary alveolar hemorrhage (with grade 3 thrombocytopenia), pulmonary fibrosis, reactivation of disease (including, but not limited to hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, herpes zoster), sepsis, septic shock, Stevens-Johnson syndrome, toxic epidermal necrolysis, tumor lysis syndrome<\/p><p><strong><em><u>Reporting of suspected adverse reactions<\/u><\/em><\/strong><\/p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Please report any adverse drug reactions via contacting Cedal Nano.<sup>(1)<\/sup><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"6\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2546\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fab fa-confluence\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tDrug Interactions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-2546\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"6\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-2546\" tabindex=\"0\" hidden=\"hidden\"><p>No\u00a0<em>in-vivo<\/em>\u00a0interaction studies have been performed.<\/p><p>When Ribocedal<sup>\u00ae<\/sup> is combined with myelosuppressive agents, the effect of Ribocedal<sup>\u00ae<\/sup> and\/or the co-administered medicinal products on the bone marrow may be potentiated. Any treatment reducing the patient&#8217;s performance status or impairing bone marrow function can increase the toxicity of Ribocedal<sup>\u00ae<\/sup>.<\/p><p>Combination of Ribocedal<sup>\u00ae<\/sup> with cyclosporine or tacrolimus may result in excessive immunosuppression with risk of lymphoproliferation.<\/p><p>Cytostatics can reduce antibody formation following live-virus vaccination and increase the risk of infection which may lead to fatal outcome. This risk is increased in subjects who are already immunosuppressed by their underlying disease.<\/p><p>Ribocedal<sup>\u00ae<\/sup> metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme. Therefore, the potential for interaction with CYP1A2 inhibitors such as fluvoxamine, ciprofloxacin, acyclovir and cimetidine exists.<\/p><p><u>Paediatric population<\/u><\/p><p>Interaction studies have only been performed in adults.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"7\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2547\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-baby\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\t Pregnancy and Lactation\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-2547\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"7\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-2547\" tabindex=\"0\" hidden=\"hidden\"><ul><li><strong>Pregnancy<\/strong><\/li><\/ul><p>There are insufficient data from the use of bendamustine hydrochloride in pregnant women. In nonclinical studies bendamustine hydrochloride was embryo-\/fetolethal, teratogenic and genotoxic. During pregnancy Ribocedal<sup>\u00ae<\/sup> should not be used unless clearly necessary. The mother should be informed about the risk to the foetus. If treatment with Ribocedal<sup>\u00ae<\/sup> is absolutely necessary during pregnancy or if pregnancy occurs during treatment, the patient should be informed about the risks for the unborn child and be monitored carefully. The possibility of genetic counselling should be considered.<\/p><ul><li><strong>Breast feeding<\/strong><\/li><\/ul><p>It is not known whether bendamustine passes into the breast milk, therefore, Ribocedal<sup>\u00ae<\/sup> is contraindicated during breastfeeding.<\/p><p>Breastfeeding must be discontinued during treatment with Ribocedal<sup>\u00ae<\/sup>.<\/p><ul><li><strong>Fertility<\/strong><\/li><\/ul><p>Women of childbearing potential must use effective methods of contraception both before and during Ribocedal<sup>\u00ae<\/sup> therapy.<\/p><p>Men being treated with Ribocedal<sup>\u00ae<\/sup>are advised not to father a child during and for up to 6 months following cessation of treatment. Advice on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility due to therapy with Ribocedal<sup>\u00ae<\/sup>.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t\t\t<div class=\"the7-e-tab-item-wrapper\" data-tab=\"8\">\n\t\t\t\t\t<div class=\"the7-e-tab-title\" aria-selected=\"false\" data-tab=\"8\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-2548\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t<span class=\"the7-e-tab-icon elementor-icon\" aria-hidden=\"true\"><i class=\"fas fa-box\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t<h5 class=\"the7-e-tab-title-text\">\n\t\t\t\t\t\t\tStorage Conditions\t\t\t\t\t\t<\/h5>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"the7-e-tab-content-2548\" class=\"the7-e-tab-content the7-e-tab-text-content\" data-tab=\"8\" role=\"tabpanel\" aria-labelledby=\"the7-e-tab-title-2548\" tabindex=\"0\" hidden=\"hidden\"><p><strong>&#8211; <\/strong>Keep the medicine in the box until it is consumed.<\/p><p>&#8211; store the medicine at temperatures below 30\u00b0 C and protect from moisture.<\/p><p>&#8211; Keep the medicine out of the reach of children and pets.<\/p><p>-For storage conditions after reconstitution or dilution of the medicinal product, see section below:<\/p><p>&#8211; The final admixture is stable for 24 hours stored under refrigerated conditions at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) or for 3 hours when stored at room temperature (15\u00b0C to 30\u00b0C or 59\u00b0F to 86\u00b0F) and room light. Administration of reconstituted and diluted Bendamustine hydrochloride for Injection must be completed within this period<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<span class=\"item-divider\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t<\/div>\n\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-2ad3237 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2ad3237\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-29ce403\" data-id=\"29ce403\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a5e1954 icon-box-vertical-align-center elementor-widget__width-auto elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile content-align-left icon-position-left icon-vertical-align-start elementor-widget elementor-widget-the7_icon_box_widget\" data-id=\"a5e1954\" data-element_type=\"widget\" data-widget_type=\"the7_icon_box_widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\n\t\t<div class=\"the7-box-wrapper the7-elementor-widget the7_icon_box_widget-a5e1954\">\t\t\t<div class=\"box-content-wrapper\">\n\t\t\t\t\t\t\t\t<div class=\"box-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"box-heading\">\n\t\t\t\t\t\t\t<a href=\"\/wp-content\/uploads\/2023\/02\/5FUEnglish.docx\">\t\t\t\t\t\t\t\tProduct Description File\t\t\t\t\t\t\t<\/a>\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-93b1403 elementor-share-buttons--view-icon elementor-share-buttons--skin-minimal elementor-share-buttons--shape-circle elementor-grid-mobile-6 elementor-share-buttons--align-left elementor-share-buttons--color-custom elementor-widget__width-auto elementor-grid-0 elementor-widget elementor-widget-share-buttons\" data-id=\"93b1403\" data-element_type=\"widget\" data-widget_type=\"share-buttons.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-grid\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_twitter\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on twitter\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-twitter\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_linkedin\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on linkedin\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-linkedin\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_whatsapp\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on whatsapp\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-whatsapp\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_telegram\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on telegram\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fab fa-telegram\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\">\n\t\t\t\t\t\t<div\n\t\t\t\t\t\t\tclass=\"elementor-share-btn elementor-share-btn_print\"\n\t\t\t\t\t\t\trole=\"button\"\n\t\t\t\t\t\t\ttabindex=\"0\"\n\t\t\t\t\t\t\taria-label=\"Share on print\"\n\t\t\t\t\t\t>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<i class=\"fas fa-print\" aria-hidden=\"true\"><\/i>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Generic Name Bendamustine Hydrochloride Brand Name \u00aeRiboCedal Drug Class Alkylating agent with purine-analog\u2013like properties Dosage Form Powder for Concentrate for Solution for Infusion 25 mg &#038; 100 mg Indications Contradications Warnings and Precautions Dosage &#038; Administration Adverse Reactions Drug Interactions Pregnancy and Lactation Storage Conditions Indications First-line treatment of chronic lymphocytic leukaemia (Binet stage B&hellip;<\/p>\n","protected":false},"author":1,"featured_media":9180,"comment_status":"closed","ping_status":"closed","template":"","dt_portfolio_category":[48],"dt_portfolio_tags":[],"class_list":["post-9194","dt_portfolio","type-dt_portfolio","status-publish","has-post-thumbnail","hentry","dt_portfolio_category-oncology-en"],"_links":{"self":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/9194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio"}],"about":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/types\/dt_portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/comments?post=9194"}],"version-history":[{"count":19,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/9194\/revisions"}],"predecessor-version":[{"id":12145,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio\/9194\/revisions\/12145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/media\/9180"}],"wp:attachment":[{"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/media?parent=9194"}],"wp:term":[{"taxonomy":"dt_portfolio_category","embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio_category?post=9194"},{"taxonomy":"dt_portfolio_tags","embeddable":true,"href":"https:\/\/cedalco.com\/en\/wp-json\/wp\/v2\/dt_portfolio_tags?post=9194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}